BioLamina CEO Klaus Langhoff-Roos discusses the challenges of scaling stem cell production from lab plates to bioreactors, ...
Biotech funding surges as companies like Pelage, Kardigan, and Kailera secure millions to innovate treatments for hair loss, ...
Bristol Myers Squibb's acquisition of Orbital Therapeutics includes OTX-201, a next-gen CAR T-cell therapy, and a proprietary ...
As timelines change, medical affairs teams must adjust their skillsets. Dr. William Soliman: We’ve seen Pfizer doing a deal ...
Hunter Smith,CFO of Rhythm Pharmaceuticals, noted that maintaining balance between investor expectations and long-term ...
In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopedics division into a standalone company, the global implications of the Most Favored Nation drug ...
In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff ...
Jonhson and Johnson announced its intention to separate its orthopaedics business to enhance both the strategic and operational focus of each company, while also improving value for stakeholders. 1 ...
Catherine discusses the recent advancements in neuroscience and rare disease innovation over the past few years. The ...
President Trump’s latest attempt at implementing International Reference Pricing- based (IRP-) methodology to regulate drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback